Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TRI-CIRA 21 - Health Canada Drug Approval Details

Approvals/Health Canada/TRI-CIRA 21

Authorized

STANDARD

TRI-CIRA 21

Apotex Inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 9cbbe04c5968a37c
Company: Apotex Inc
Type: Standard

Approval Details

Approval Id: 9cbbe04c5968a37c
Drug Approval Canada Name: TRI-CIRA 21
Product Name: TRI-CIRA 21
Status: Marketed
Status Date: 2021-03-19
Original Market Date: 2021-03-19
Din: 02508087
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 68:12.00
Atc Original: G03AB09 NORGESTIMATE AND ETHINYLESTRADIOL
Atc Name: g 03 ab 09
Aig Number: 0636783002
Company Name: Apotex Inc
Company Address: 150 Signet Drive, Toronto, Ontario, Canada, M9L 1T9
Company Detail Path: /organization/apotex-inc

Company Information

Pharmaceutical Company Name: Apotex Inc
Country Name: Canada
Province Name: Ontario
City Name: toronto,ontario,country_ca
Address: 150 Signet Dr

Active Ingredients

ETHINYL ESTRADIOL

0.035 MG

NORGESTIMATE

0.18 MG

NORGESTIMATE

0.25 MG

NORGESTIMATE

0.215 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

9cbbe04c5968a37c

Type

Standard

Back to Health Canada Approvals